ZNF521 and ovarian carcinoma: Taken together the analyses of different public genomic databases indicate that ZNF521 is: i) amplified in 6% of ovarian carcinoma cases and ii) associated to poor survival in ovarian cancer patients [18–20] (S1 Fig).